Our findings also suggest that SLC16A1 could serve as a potential therapeutic target, potentially enhancing the sensitivity of CCA patients to chemotherapy and reducing the occurrence of drug resistance. This evidence concerns the gene SLC16A1 and cholangiocarcinoma.